is a weekly electronic
. It is published online every Thursday evening (with the exception
of e-alerts). At the same time, the current issue's table of contents is sent by
email to all subscribers.
Pdf versions of the weekly issues as well as the individual articles can be downloaded
from the Eurosurveillance
website from the week following publication.
Eurosurveillance print compilation
In addition to the online publication, special issues and topical compilations of
selected material from the online issues are published in printed form.
articles should be cited as indicated at the top of the
web version of the articles, using the electronic page number. Although part of
the online content appears in print, the page numbers in print compilations and
pdf files should not be cited. Correct citations with electronic page numbers can
be found at the top of each article on the website and also in the pdf and the print
An example of a correct citation is:
Scheutz F, Møller Nielsen E, Frimodt-Møller J, Boisen
N, Morabito S, Tozzoli R, Nataro JP, Caprioli A. Characteristics of the enteroaggregative
Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak
of haemolytic uraemic syndrome in Germany, May to June 2011. Euro Surveill.
Rapid communications are timely, authoritative short reports on important communicable
disease findings and events where rapid dissemination of information could potentially
lead to a prompt change in an ongoing public health situation or create awareness
for topics we consider to be of timely relevance. These articles are usually published
within a few days of submission, but when necessary, publication can be arranged
within hours of submission (see e-alerts). They undergo rapid independent peer review
by at least one expert in the field.
To allow for such rapid processing, these articles are short, usually around 1,000
words, and have a minimum of eight and up to about 20 references and four illustrations
(figures or tables). The abstract should not exceed 75 words.
are published ad hoc to disseminate information about
an important event that should not wait until the next regular publication of Eurosurveillance
Subscribers receive an email as soon as the e-alert is posted on the website.
Prompt dissemination of preliminary information about communicable disease events
is an important part of public health action. Authors of rapid communications and
e-alerts are encouraged to later submit fuller accounts to Eurosurveillance
in the form of a regular article.
provide original results from studies on any
aspect of communicable disease epidemiology, prevention and control. These papers
should include new data or insights of public health importance and consist of about
3,500 words, a minimum of 15 and up to around 30 references and six illustrations
(figures or tables). We encourage authors to follow the
for reporting randomised
controlled trials. Research articles should usually follow the IMRaD structure
(Introduction, Methods, Results and Discussion).
Surveillance and outbreak reports:
Surveillance articles should
focus on epidemiological trends regarding a specific disease or a group of diseases
with data from a national or international surveillance system, but they could also
be an analysis of a surveillance system or a description of a new surveillance system.
Longer reports on national or international outbreaks should be submitted once the
outbreak has been fully investigated and focus on new or unexpected aspects and
on lessons learnt. The length of these articles is up to ca. 3,500 words, with a
minimum of 15 and up to around 30 references and six illustrations (figures or tables).
We encourage authors to follow the STROBE guidelines
that were set up for observational studies i.e. case-control, cohort and cross-sectional studies.
provide a comprehensive state-of-the-art overview
of issues of major public health importance within the field of communicable disease
surveillance, prevention or control. They usually are about 4,000 words in length,
and contain up to 80 references and six illustrations (figures or tables). All review
articles should explain the search strategy and selection criteria, justify the
inclusion/exclusion of material and state the sources. For systematic reviews,
we encourage authors to follow the PRISMA guidelines
should provide an analysis of a specific aspect or
function of communicable disease surveillance, prevention or control in at least
five European countries, and present an in-depth comparison of systems and/or data.
The average length of these articles is 3,500 words with a minimum of 15 and up
to around 30 references and six illustrations (figures or tables).
provide an insightful analysis of practices, policies
and guidance on communicable disease prevention and control, as well as guidance
on developments in the field of vaccines and immunisation. These articles have an
average length of 2,000 words, and contain up to 20 references and four illustrations
(figures or tables).
The following article categories are not peer reviewed. However, we may consult
an expert for advice on the content of such items.
are written by experts invited to comment on articles
and special topics covered by Eurosurveillance
and usually have a maximum
of two authors. Editorials are usually 1,500 words long and contain a maximum of
20 references and four illustrations (figures or tables).
Letters to the editor
comment on recent Eurosurveillance
articles and should be submitted within four weeks after the publication of the
article in question. They are intended to stimulate scientific discussion and are
not a format for the publication of original data. Their average length is 600 words,
with five or fewer references.
should focus on content and contain up to 2,000
words, 10 references (including, when possible, links to full reports of conference
activities) and no illustrations. They should have no more than two authors. Before submitting a meeting report, please contact
the editorial team.
are short texts related to current public health events, either
authored or commissioned by the Eurosurveillance
editorial team. Their
length is usually 400 words, with five or fewer references and no illustrations.
News do not have more than one or two authors.
All submissions should be sent through the Eurosurveillance online submission system
An online author tutorial is available, if you have any difficulties during the submission process.
All submissions should contain the following information:
- the article category;
- a declaration that the material is original and has not been submitted elsewhere;
- a declaration that all authors have seen and approved the final manuscript;
- a declaration that the corresponding author, on behalf of all co-authors,
has read and agreed to the terms of the Eurosurveillance
data protection notice;
- a declaration that informed consent has been obtained from persons whose details
are described in articles (or from the persons’ guardians) that this information
may be published;
- a statement on funding and potential competing interests of the authors;
- where appropriate, information on approval of the work by an ethics committee;
- proof of permission to use figures or tables that are adapted or reproduced
from other publications.
The following material should be uploaded as separate files:
- a covering letter;
- an anonymised manuscript text in Word format (pdf files cannot be evaluated) including
an abstract of appropriate length and a minimum number of eight references for rapid
communications and 15 for regular articles. All author-identifiable information – authors’
names, affiliations and contributions as well as any acknowledgements – should
NOT be included in the document. No illustrations (figures or tables) should
be included in this document;
- authors’ names and affiliations (in the format for publication). The first name of each
author should be given in full (i.e. an initial should not be given). Where a collective
author is included (e.g. a working group or disease-specific network) and if the persons
comprising the group are to be included at the end of the article, please list each
person in this file;
- authors’ contributions: the contribution of each author to the article should be
described. This information will be published at the end of the article;
- all figures in an appropriate format (see details in the section on
formatting and style),
- all tables in Word format;
- a scan of the
agreement with authors signed by the corresponding author on behalf of all authors.
File names of uploaded files must not contain any author-identifiable information that may
lead to identification of the author.
After all files and information have been uploaded in the submission system, the
corresponding author is responsible for checking and approving the pdf. Approval of
the pdf is required for the article to be sent to the editorial office.
The pdf that the reviewer will receive contains only the manuscript text and any
figures and tables. For rapid communications, we also give reviewers access to the
source files, in case they wish to comment directly in the text. For this reason,
authors of rapid communications must ensure that all personal information in the
properties of the manuscript text, figures and tables is removed before submission.
See instructions on how
to remove personal information from Microsoft Word or Excel files.
Ensuring that the appropriate files contain no author-identifying information allows the
relevant files to be sent to reviewers. If the above conditions regarding anonymity of files
and file names are not met, the submission will be returned to the authors, for them to
amend and resubmit.
Submissions should conform to the uniform requirements for manuscripts submitted
to biomedical journals as detailed in: Uniform requirements for manuscripts submitted
to biomedical journals. International Committee of Medical Journal Editors. Med
Educ. 1999; 33(1):66-78 (http://www.icmje.org/index.html
Eurosurveillance does not publish supplementary material. All necessary
information should be integrated in the article, while observing the word limit.
In exceptional cases, where strong reasons preclude publication of certain information
as part of the article, the authors have the option to make such material available
on an independent website and to provide a link to this website in the article.
Such material is not edited by Eurosurveillance and Eurosurveillance
is not responsible for the content.
Articles should be written in clear, appropriate and scientific language that is
free of jargon. Avoid abbreviations when possible and define them when you first
use them. Please use United Kingdom English spelling.
should be interesting, informative, accurate and as short
as possible. They should contain the place/country and the time period covered in
A maximum of eight keywords suitable for indexing should
be provided. Please select from the list provided
and add others if needed.
Separate the keywords by a semi-colon (;).
of regular articles should stay within the limit of 150
to 200 words, those of rapid communications should not exceed 75 words. Abstracts
do not contain subheadings.
An introduction should put the topic into perspective
using up-to-date references, and clearly state the objective of the work and its
relevance. The relevant methods should be presented at an appropriate level of detail;
molecular diagnostic techniques that are published or standard, for example, can
be named and referenced and do not need to be described in detail. It is important
to make it clear at all times which results are the work of the authors, presented
as part of the article, and which are already known and given as background or for
comparison. If tables and figures are provided, the text should shortly describe
and summarise the content, but not unnecessarily repeat the information; the reader
should be able to understand text and illustrations independently of each other.
The European and international relevance should be discussed with relevant references,
and where appropriate, lessons learnt and recommendations for the future should
Tables and figures
Tables and figures are inserted after the paragraph in which they are mentioned.
Any references given in them are numbered after the citations in the text, i.e.
the numbering does not take into account the position of the table or
figure in the text.
Figure/table titles should not contain abbreviations and be as short as possible
and mention the disease, place and date as well as number of cases/samples shown,
so that it can be clearly understood what is shown. Further information needed to
understand the figure or table is presented in the footnote under the illustration,
together with explanations of all abbreviations and information on the source of
the data. Footnotes added to specific entries in the table or figure are numbered
as superscript a, b, c, etc. in order of appearance. The reader should be able to
understand an illustration without referring to explanations in the text.
Tables and figures that have already been published can only be accepted under specific
circumstances. In such cases the authors are required to obtain permission from
the copyright holder to reproduce the illustration in question. Copyright also needs
to be observed, for example, for maps used as a background for entering data.
should be sent in Word format. They must be uploaded as separate files.
should be uploaded as separate, editable files. Graphs
should be provided in Excel format. If that is not possible, graphs, as well as phylogenetic trees etc,
have to be submitted as vector files such as .pdf, .eps, .wmf, .emf, .svg . could be given.
All the programmes used to create graphs should be able to export a file in at least one of these formats.
Not all pdfs are vector files: Illustrations should be exported as a pdf directly from the programme in which
they were created, rather than exporting the illustration in another format and then subsequently
saving as a pdf.
Pictures of illustrations simply copied into the above formats cannot be used because they cannot be edited.
We need the illustration to be linked to the original data. Bitmap files (.jpg,
.bmp, .gif, etc) are not acceptable. Maps
should be provided
as vector files (.pdf, .eps, .wmf, .emf, .svg). Preferably the maps should not include
bitmap elements (i.e. map as a picture in the background). Only photographs
should be given as high-resolution bitmap files (.jpg, .tif, etc.). They should
be provided as stand-alone original files, and not included in Word or PowerPoint
Citations are numbered in the order of appearance in the text. Reference numbers
are placed in square brackets  in the text. References cited in a table or figure
legend should be numbered after the citations in the text.
Papers that are accepted for publication can be cited as forthcoming. Papers not
yet accepted for publication cannot be cited. The source of such information can
be indicated in parentheses in the text, either as data not shown, if the information
comes from one of the authors, or as personal communication, if the information
comes from someone else. Personal communications must include the name of the person
and the date the communication took place.
References should be formatted according to the uniform requirements for manuscripts
submitted to biomedical journals’(Vancouver style). Do not use italics, bold or
#. Author of article AA, Author of article BB, Author of article CC. Title of article.
Abbreviated Title of Journal. Year;vol(issue):page number(s).
1. Geck MJ, Yoo S, Wang JC. Assessment of cervical ligamentous injury in trauma
patients using MRI. J Spinal Disord. 2001;14(5):371-7.
If there are more than six authors, list the first six authors followed by et al.
1. Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation
of interstitial excitatory amino acid concentrations after cortical contusion injury.
Brain Res. 2002;935(1-2):40-6.
More samples of reference formats can be seen at:
Authors and acknowledgements
All listed authors should have made substantive intellectual contributions to the
article, be aware of its submission to Eurosurveillance
and able to account
for its content. The contribution of each author to the article must be stated: this
information will be shown at the end of the published article.
We do not limit the number of authors, but for the rapid communications
it may be more appropriate to list the names of people who have not contributed
directly to the production of the article in the acknowledgements. You may acknowledge
anyone who has helped you with any aspect of the report, but it is always the corresponding
author’s responsibility to obtain permission from anyone being acknowledged.
Please include complete information about each author (full name, affiliation and
the name of the institution, city and country in which the work was done). Clearly
identify and provide telephone number and email address for the corresponding author.
In our submission system,
authors can also include an ORCID (Open Researcher and
Contributor ID), if they have one. We encourage authors to use this system.
It is possible to provide a collective name as an author (working group, disease-specific
network, etc.). The members of such a group can be listed at the end of the article
and will appear in PubMed/MEDLINE indexation. In the
online submission system,
the corresponding author will be asked whether there is a collective author and for any
names of members of the group or network to be listed.
A statement on funding for the work described in the manuscript should be included.
Although the database of the Global Initiative on Sharing All Influenza Data (GISAID) is publicly
accessible, it is not open access, and attention should be paid to correct attribution of the data used.
You should acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s
EpiFlu™ Database on which the research is based, and to refer to the GISAID website (www.gisaid.org).
In addition to an appropriate acknowledgement, we recommend including a table in the Methods section,
listing all sequences with the respective background information, unless there is an unmanageable number of them.
Examples of how to do this can be found here:
Eurosurveillance allows authors to submit material that has previously
been published in a language other than English, if dissemination in English would
be beneficial from a scientific or public health perspective to a wider readership
that cannot read the primary publication or has limited access to it. Such publication
will mainly be considered for short articles on topics that have been previously
covered in the bulletins of the national surveillance institutes. Eurosurveillance
aims to add value to these publications, usually by widening the discussion to include
other European countries, and including additional references. Longer articles are
usually not accepted for secondary publication.
It should be clear from the submission that it is secondary publication, and permission
from the editors of the primary publication must be sought and documented in advance.
If published, the primary publication should be clearly acknowledged with a reference
and, where possible, web link to the original material.
Prospective authors should follow the guidelines in the section III.D.3. of the
International Committee of Medical Journal Editors' uniform requirements for manuscripts
submitted to biomedical journals (http://www.icmje.org/publishing_4overlap.html)
Secondary publications are subject to the normal Eurosurveillance review
Evaluation and peer review
Upon submission, the articles are screened by the editorial team and scheduled for
discussion in the next editorial meeting. Papers received without the necessary
accompanying material such as signed
agreement with authors, conflict of interest declaration, manuscript text,
abstract and figures in the correct length and format, etc. are not considered as
submissions and will not be evaluated.
Manuscripts that pass the first evaluation will be sent for peer review to at least
two (for rapid communications and e-alerts at least one) independent experts in
the field. While we try to avoid delays, this part of the process relies on the
availability and cooperation of the referees and can take considerable time. The
reviewer is always a person working outside the team or the department of the authors,
and is usually from a different institute and/or country. We follow a policy of
double-blind peer review where both the authors’ and the reviewers’ identities are
In the online submission system,
authors can track the status of their submission.
If they wish to contact the editorial office about their manuscript at any point, this
should be done by sending an ad hoc email through the submission system (via ‘Action links’).
Upon receipt of the reviews, the article is evaluated in detail by the editorial
team taking into account the reviewers' comments and recommendations and is scheduled
for the next available editorial meeting where a decision will be made whether to
proceed with the manuscript or to reject it. If the reviewers' opinions are conflicting,
the article may be sent for a further review.
If the decision is made to proceed with the manuscript, the reviewers’ comments
and suggestions are sent to the authors as guidelines for the preparation of a revised
draft. On rare occasions, we may amend the reviewer’s comments before they are sent to the authors,
to take into account particular sensitivities or remove passages that are clearly intended as
recommendations not for the authors but for the editor. When at least two reviews are obtained
(for all regular articles and for some rapid communications), the anonymised comments for the
authors will be shared with the other reviewer(s) of the manuscript. The editorial decision
will also be passed on to the reviewers.
The invitation to submit a revised manuscript does not imply that the manuscript
will eventually be accepted for publication. Together with the revised manuscript,
the authors are required to return a detailed, point-by-point response to the reviewers'
comments. The editorial team may decide to consult the original referees once more
to judge whether their concerns have been addressed satisfactorily.
The revised manuscript is scheduled for final evaluation and editing. Our papers
are rigorously edited for content and style, and the authors may need to provide
further information, corrections and clarifications at this stage. Because the editing
process itself can bring up points that have gone unnoticed before, we do not formally
accept a manuscript before editing is complete.
Once the editor and corresponding author have agreed on the final version of the
manuscript, a final copy is sent to the author for approval and the paper is published
in one of the next available issues, usually within two weeks from finalisation
of the text. This may be longer if the article is published as part of a special
thematic issue or in the context of a particular event.
Rapid communications and e-alerts follow the same steps but are processed with priority
to ensure timely dissemination of important public health information.
Some articles are processed by an editorial board member who is not working at ECDC.
To avoid potential conflicts of interest, regular articles authored by our colleagues
at ECDC are processed, whenever possible, by an editorial board member who is not
working at ECDC, whenever possible. This includes initial evaluation, selection
of peer reviewers, evaluation of the reviewers’ comments and evaluation of the
revisions. After that, the editorial team in Stockholm are responsible for the editing.
The editorial team should be informed immediately of any errata or corrections to
be made. Such changes are made immediately in the original article as well as the
pdf, together with an editorial note explaining the nature and date of the change.
Corrections and errata are usually published in the first issue of every month.
Contacting the editorial team
If you have any questions about Eurosurveillance
, please contact our editorial
team at email@example.com
The opinions expressed by authors contributing to Eurosurveillance
do not necessarily reflect the opinions of the European Centre for Disease Prevention
and Control (ECDC) or the editorial team or the institutions with which the authors
are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible
for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance
site is designed to support,
not replace, the relationship that exists between a patient/site visitor and his/her
physician. Our website does not host any form of commercial advertisement.
Eurosurveillance [ISSN] - ©2007-2013. All rights reserved